Literature DB >> 12440609

Seventeen-year experience with 1,083 heart transplants at a single institution.

Daniel Marelli1, Hillel Laks, Jon A Kobashigawa, Jessica Bresson, Abbas Ardehali, Fardad Esmailian, Mark D Plunkett, Bernard Kubak.   

Abstract

BACKGROUND: Heart transplantation is the most accepted treatment for end-stage heart disease. A review of 1,083 consecutive transplants (1984 to 2001) was undertaken.
METHODS: Adult recipients were divided into quartiles. The last 540 transplants were combined. Three eras were created from these, 1984 to 1991, 1991 to 1995, and 1995 to 2001, with three age groups: 0 to 18 years, 19 to 61 years, and 62 to 74 years. All patients have at least 1 year of follow-up time. End points were survival, rejection, and graft coronary artery disease.
RESULTS: There were 1,012 patients. Donor age, graft ischemic time, and the proportion of elderly recipients and nonstandard donor hearts have increased in the current era. Actuarial 60-month survivals of recipients after 1995 were 80.7% (0 to 18 years); 75.3% (19 to 61 years); and 76.2% (>62 years). The current era children and younger adult groups demonstrated improved results when compared with previous eras (p = 0.003 and p = 0.05). Rejection episodes equal to or greater than ISHLT grade 3A per person per year improved to 0.15 in the current era (p < 0.001). During the three eras, older recipients (>62 years) demonstrated fewer episodes of rejection when compared with other adults (0.13 versus 0.58, p = 0.03). Deaths attributed to graft coronary artery disease decreased from 11% to 5% from era 2 to era 3. Regression analysis revealed a mild effect of donor age on survival and graft coronary artery disease (hazard ratio = 1.02, p = 0.001; hazard ratio = 1.039, p < 0.001, respectively). Recipient predictors of graft coronary artery disease were diagnosis of ischemic cardiomyopathy (hazard ratio = 1.6, p = 0.014) and congenital heart disease (hazard ratio = 3.41, p = 0.02).
CONCLUSIONS: Improved survival in the current era may be attributed to better organ preservation, improved immunosuppression and control of infection, and less life-threatening graft coronary artery disease.

Entities:  

Mesh:

Year:  2002        PMID: 12440609     DOI: 10.1016/s0003-4975(02)03933-4

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  5 in total

1.  Improved survival in heart transplant recipients in the United States: racial differences in era effect.

Authors:  Tajinder P Singh; Christopher Almond; Michael M Givertz; Gary Piercey; Kimberlee Gauvreau
Journal:  Circ Heart Fail       Date:  2011-01-12       Impact factor: 8.790

Review 2.  Update in adult congenital cardiac surgery.

Authors:  Sabine H Daebritz
Journal:  Pediatr Cardiol       Date:  2007-05-04       Impact factor: 1.655

3.  Modified inferior vena caval anastomosis to reduce tricuspid valve regurgitation after heart transplantation.

Authors:  Daniel Marelli; Scott C Silvestry; Donna Zwas; Paul Mather; Sharon Rubin; Anthony F Dempsey; Louis Stein; Evelio Rodriguez; James T Diehl; Arthur M Feldman
Journal:  Tex Heart Inst J       Date:  2007

4.  Contemporary characteristics and outcomes of adults with familial dilated cardiomyopathy listed for heart transplantation.

Authors:  Mohamed Khayata; Sadeer G Al-Kindi; Guilherme H Oliveira
Journal:  World J Cardiol       Date:  2019-01-26

Review 5.  Heart Transplant in Older Adults.

Authors:  Joshua A Rushakoff; Evan P Kransdorf
Journal:  Curr Transplant Rep       Date:  2022-01-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.